Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Long-Term Investments (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Long-Term Investments for 11 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For Q3 2025, Long-Term Investments changed 0.0% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, changed 0.0%, while the annual FY2024 figure was $2.0 million, 0.0% changed from the prior year.
  • Long-Term Investments hit $2.0 million in Q3 2025 for Cartesian Therapeutics, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $2.0 million in Q3 2021 and bottomed at $2.0 million in Q3 2021.
  • Average Long-Term Investments over 5 years is $2.0 million, with a median of $2.0 million recorded in 2021.
  • Year-over-year, Long-Term Investments surged 45.03% in 2021 and then changed 0.0% in 2022.
  • Cartesian Therapeutics' Long-Term Investments stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $2.0 million, $2.0 million, and $2.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.